Cefiderocol

Cefiderocol has been studied in 1 paper since 2026: 1 observational study in people; 1 in the past year. The newest story, Oct 26, 2026: “Lab frailty score linked to death in one drug-resistant infection”.

Intervention

1 paper studies it1 findingUpdated Oct 26, 2026

1 new paper in 30 daysSee all 1

“No mortality difference was observed between cefiderocol- and colistin-based regimens.”

The prognostic value of a laboratory-based frailty index (FI-Lab) in carbapenem-resistant Acinetobacter baumannii infections: a multicentre cohort studyEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026doi:10.1007/s10096-026-05641-y

1 lab in 1 country

Funder: Universita degli Studi di Bari Aldo Moro

Humans1

What did studies of Cefiderocol find?

Studies of Cefiderocol measured 1 outcome; the most studied are mortality (1 study).

Mortality

no changein humans1

1 study

Cefiderocol has no effect on mortality in humans.
“No mortality difference was observed between cefiderocol- and colistin-based regimens.”
HumansCompared with colistin-based regimens in patients with CRAB infectionscefiderocol-based regimens
Lab frailty score linked to death in one drug-resistant infection
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical MicrobiologyOct 26, 2026

Latest

1 paper in 12 months

European Journal of Clinical Microbiology & Infectious DiseasesOct 26

Lab frailty score linked to death in one drug-resistant infection

Each 0.10-point higher score was linked to greater 30-day death risk, with a relative-risk measure called a hazard ratio of 1.68.Each 0.10-point higher score was linked to greater 30-day death risk, with a relative-risk measure called a hazard ratio of 1.68.

Cohort · 199 peopleBiomarkers

Paper

Cefiderocol

What did studies of Cefiderocol find?

Latest

Lab frailty score linked to death in one drug-resistant infection

Related